Disease-Based Libraries
     
Home > PRODUCTS > Targeted Libraries > Disease-Based Libraries

Design your focused library

Newsletter Subscription

Stay updated with our new products and services. You can unsubscribe at any time.


Disease-Based Libraries
Hepatitis C Virus Targeted Libraries

Hepatitis C Virus Targeted LibrariesOTAVAchemicals offers HCV-related targeted libraries. The libraries have been designed using machine learning (artificial neural networks and Bayesian statistics) and molecular docking towards specific protein targets related to HCV life cycle.

 

 

Read more...
 
Cancer Targeted Libraries

Diabetes Targeted LibrariesCancer is a group of diseases (over 100 types) involving abnormal cell growth with the potential to invade or spread to other different tissues. Today the problem of cancer is actual and needs a lot of efforts to solve it. OTAVAchemicals offers Cancer Targeted Libraries designed with Ligand-based and Receptor-based approach. These libraries are proposed for screening in cancer-associated research and drug development projects.

Read more...
 
Diabetes Targeted Libraries

Diabetes Targeted LibrariesHundreds millions of people have diabetes worldwide. Diabetes is estimated to have resulted in 1.5 to 5.0 million deaths each year. Today researchers are making a lot of efforts to develop new, more effective compounds to treat this disease. OTAVAchemicals offers Diabetes Targeted Libraries designed with Ligand-based and Receptor-based approach. These libraries are proposed for screening in diabetes-associated research and drug development projects.

Read more...
 
Alzheimer's Disease Targeted Libraries

Alzheimer's disease targeted librariesDuring the past decades, several agents have been approved that enhance cognition of Alzheimer's disease (AD) patients. However, the effectiveness of these treatments are limited or controversial and they do not modify disease progression. Recent advances in understanding AD pathogenesis have led to the development of numerous compounds that might modify the disease process. Taking into account AD complexity, it becomes clear that polypharmacology with drugs targeting different sites could be the future treatment approach and a majority of the recent drugs under evaluation seems to act on multiple targets.

Read more...
 


SSL